TrkB 분자 정보
Molecule Name
Neurotrophic tyrosine kinase receptor type 2
분자 별명
NTRK2,TRKB,GP145-TrkB
Drug Development Progress
임상 약물 수13
시판 약물 수5
최고 연구 개발 단계Approved
표적 별명
EC:2.7.10.1，EC 2.7.10，Tropomyosin-related kinase B，Trk-B，GP145-TrkB，NTRK2，Neurotrophic Receptor Tyrosine Kinase 2，Neurotrophic Tyrosine Kinase Receptor Type 2，TRKB，Neurotrophic Tyrosine Kinase， Receptor， Type 2，BDNF-Tropomyosine Receptor Kinase B，BDNF/NT-3 Growth Factors Receptor，Tyrosine Kinase Receptor B，TrkB Tyrosine Kinase，EC 2.7.10.1，EIEE58，OBHD，Receptor， trkB
분자 배경
This gene encodes a member of the neurotrophic tyrosine receptor kinase(NTRK)family.This kinase is a membrane-bound receptor that upon neurotrophin binding,phosphorylates itself and members of the MAPK pathway.Signalling through this kinase leads to cell differentiation.Mutations in this gene have been associated with obesity and mood disorders.
TrkB 제품 목록
You Have Viewed 0 Of 0 Results
임상 약물 정보
| 영어 이름 | 연구 코드 | 연구 개발 단계 | 회사 | 적응증 | 임상 시험 |
|---|---|---|---|---|---|
| Lestaurtinib | SPM-924; A-154475.0; KT-5555; SP-924; CEP-701 | Phase 3 Clinical | Kyowa Hakko Kirin Co Ltd | Bone Marrow Neoplasms; Leukemia; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Neuroblastoma; Polycythemia Vera; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Primary Myelofibrosis; Prostatic Neoplasms; Psoriasis; Thrombocythemia, Essential | 상세 |
| Merestinib | 5OGS5K699E; LY-2801653 | Phase 2 Clinical | Eli Lilly And Company | Biliary Tract Neoplasms; Bone metastases; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cholangiocarcinoma; Colorectal Neoplasms; Gallbladder Neoplasms; Leukemia, Myeloid, Acute; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Microsatellite instability-high cancer; Neoplasm Metastasis; Neoplasms; Pancreatic Neoplasms; Skin Melanoma; Solid tumours | 상세 |
| FCN-011 | FCN-011 | Phase 2 Clinical | Solid tumours | 상세 | |
| MT-200605 | MT-200605; MT200605 | Phase 2 Clinical | Shaanxi Micot Pharmaceutical Technology Co Ltd | Brain Injuries; Ischemic Stroke; Nervous System Diseases; Obesity; Overweight; Stroke | 상세 |
| Emzeltrectinib | CT-3417; TQB-3558 | Phase 1 Clinical | Beijing Centaurus Biopharma Co Ltd, Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd | Solid tumours | 상세 |
| ACD-856 | ACD-856 | Phase 1 Clinical | Alzecure Pharma Ab | Alzheimer Disease; Cognition Disorders | 상세 |
| HG-030 | HG-030 | Phase 1 Clinical | Hitgen Inc | Solid tumours | 상세 |
| FB_-1002 | FB_-1002; FB-1002; 4B02-01 | Phase 1 Clinical | 4b Technologies (Suzhou) Ltd | Amyotrophic Lateral Sclerosis; Depressive Disorder | 상세 |
| FB-1001 | FB_-1001; FB-1001; FB1001 | Phase 1 Clinical | 4b Technologies (Suzhou) Ltd | Glaucoma; Glaucoma, Angle-Closure; Optic Nerve Diseases; Optic Neuropathy, Ischemic | 상세 |
| 1-D-228 | 1D228; 1-D-228 | Phase 1 Clinical | Guangdong Lewwin Pharmaceutical Research Institute Co Ltd, Guangzhou Zhongkelian Pharmaceutical Research Co Ltd | Carcinoma, Non-Small-Cell Lung | 상세 |
| BrAD-R13 | BrAD-R13; BrADR13 | Phase 1 Clinical | Shenzhen Braegen Pharmaceutical Co Ltd | Alzheimer Disease | 상세 |
| T-1301 | T-1301; DBPR-216; BPR-1J481; BPR1J481 | Phase 1 Clinical | Taivex Therapeutics Corp | Lymphoma; Solid tumours | 상세 |
| Paltimatrectinib | PBI-200 | Phase 1 Clinical | Pyramid Biosciences | Brain Neoplasms; Desmoplastic Small Round Cell Tumor; Solid tumours | 상세 |
시판 약물 정보
| 영어 이름 | 연구 코드 | 연구 개발 단계 | 회사 | 가장 빠른 브랜드 이름 | 가장 빠른 승인 국가 | 가장 빠른 적응증 | 가장 빠른 승인 회사 | 가장 빠른 승인 날짜 | 적응증 | 임상 시험 |
|---|---|---|---|---|---|---|---|---|---|---|
| Taletrectinib Adipate | DS-6051b; DS-6051a; DS-6051; AB-106; IBI-344 | Approved | Daiichi Sankyo Co Ltd | 达伯乐, DOVBLERON, IBTROZI | Mainland China | Carcinoma, Non-Small-Cell Lung | AnHeart Therapeutics Co Ltd | 2024-12-17 | Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Metastatic breast cancer; Neoplasms; Solid tumours | 상세 |
| Entrectinib | NMS-E628; RXDX-101; RG-6268 | Approved | Nerviano Medical Sciences Srl | Rozlytrek, 罗圣全 | Japan | Carcinoma, Non-Small-Cell Lung | Chugai Pharmaceutical Co Ltd | 2019-06-18 | Brain Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Central Nervous System Neoplasms; Cholangiocarcinoma; Colorectal Neoplasms; Glioma; Head and Neck Neoplasms; Hematologic Neoplasms; Hepatic Insufficiency; Leukemia, Myeloid, Acute; Lymphoma, Large-Cell, Anaplastic; Lymphoproliferative Disorders; Melanoma; Neoplasms; Neuroendocrine Tumors; Ovarian Neoplasms; Pancreatic Neoplasms; Salivary Gland Neoplasms; Sarcoma; Solid tumours; Thyroid Cancer, Papillary | 상세 |
| Larotrectinib sulfate | LOXO-101; ARRY-470; BAY-2757556 | Approved | Array Biopharma | Vitrakvi, 维泰凯 | United States | Solid tumours | Bayer Healthcare | 2018-11-26 | Breast Neoplasms; Carcinoma, Ovarian Epithelial; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Central Nervous System Neoplasms; Colonic Neoplasms; Colorectal Neoplasms; Endometrial Neoplasms; Ependymoma; Esophageal Neoplasms; Fibrosarcoma; Glioma; Head and Neck Neoplasms; Hematologic Neoplasms; Hepatoblastoma; Histiocytic Sarcoma; Histiocytosis, Langerhans-Cell; Leukemia; Liver Neoplasms; Lung Neoplasms; Lymphoma; Lymphoma, Non-Hodgkin; Medulloblastoma; Melanoma; Multiple Myeloma; Neoplasms; Neoplasms, Germ Cell and Embryonal; Neuroblastoma; Neuroectodermal Tumors, Primitive, Peripheral; Osteosarcoma; Ovarian Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms; Rectal Neoplasms; Rhabdoid Tumor; Rhabdomyosarcoma; Sarcoma; Sarcoma, Ewing; Skin Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Thyroid Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Uterine Neoplasms; Wilms Tumor; Xanthogranuloma, Juvenile | 상세 |
| Repotrectinib | TPX-0005; BMS-986472; ZL-2308 | Approved | Turning Point Therapeutics Inc | Augtyro, 奥凯乐 | United States | Carcinoma, Non-Small-Cell Lung | Bristol-Myers Squibb Company | 2023-11-15 | Brain metastases; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Hepatic Insufficiency; Lymphoma; Neoplasms; Solid tumours | 상세 |
| Cabozantinib S-malate | XL-184; BMS-907351; RO7047650; RO-7047650 | Approved | Exelixis Inc | Cometriq, Cabometyx | United States | Thyroid Neoplasms; Carcinoma, Neuroendocrine | Exelixis Inc | 2012-11-29 | Adenocarcinoma, Clear Cell; Adenocarcinoma, Follicular; Adenoma, Islet Cell; Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Astrocytoma; Bile Duct Neoplasms; Bone metastases; Brain metastases; Brain Neoplasms; Breast Neoplasms; Carcinoma, Adenosquamous; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Merkel Cell; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Papillary; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Central Nervous System Neoplasms; Cholangiocarcinoma; Colorectal Neoplasms; Endometrial Neoplasms; Fallopian Tube Neoplasms; Gastroenteropancreatic neuroendocrine tumor; Glioblastoma; Glioma; Gliosarcoma; Hepatic Insufficiency; Hepatoblastoma; HIV Infections; Kidney Neoplasms; Leiomyosarcoma; Leukemia, Myeloid, Acute; Lymphoma; Medullary thyroid cancer (MTC); Melanoma; Meningioma; Multiple Myeloma; Neoplasm Metastasis; Neoplasms; Neoplasms, Germ Cell and Embryonal; Neuroblastoma; Neuroendocrin | 상세 |